Evidence map›Paper›PMID 32982183›Full record

ReviewDrug design, development and therapy2020

Bacterial Natural Compounds with Anti-Inflammatory and Immunomodulatory Properties (Mini Review).

Anahita Jenab, Rasoul Roghanian, Giti Emtiazi

Open access · goldAbstract readReview
In one paragraph

Review in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Dietary Encapsulation of a NovelAntioxidants (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Plants (Basel, Switzerland) · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Challenges and limitations in using bacterial metabolites as immunomodulators.Frontiers in cellular and infection microbiology · 2025
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Anahita JenabBiological Science and Technology, Department of Cellular and Microbiology, University of Isfahan, Hezar Jerib, Isfahan, Iran.
Rasoul RoghanianBiological Science and Technology, Department of Cellular and Microbiology, University of Isfahan, Hezar Jerib, Isfahan, Iran.
Giti EmtiaziBiological Science and Technology, Department of Cellular and Microbiology, University of Isfahan, Hezar Jerib, Isfahan, Iran.ORCID 0000-0003-3879-9076
University of Isfahan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation is part of the body's complex biological response to harmful stimuli such as damaged cells, pathogens, or irritants. It is a protective response involving blood cells, immune cells, and molecular mediators. The inflammation not only can eliminate the primary cause of cell injury but also clears out necrotic cells, tissue damaged from the original insults and inflammatory process. Furthermore, it can initiate tissue repair. Pro-inflammatory cytokines are produced predominantly by activated macrophages and are involved in the up-regulation of inflammatory reactions. They are involved in further regulating inflammatory reactions. There is ample evidence that some pro-inflammatory cytokines, such as interleukin 1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α), are involved in the pathological pain process. Some of the natural compounds promote cytokines production and inhibit inflammatory responses. The natural compounds which are produced from microorganisms such as omega-3 fatty acid, cyclic peptide, antimicrobial peptide, oligosaccharides, and polysaccharides can reduce inflammation and could be easily incorporated into the diet without any adverse effects. For example, SCFA (short-chain fatty acids), peptide bacteriocin, and polycyclic peptide bacteriocin (nisin) could be used in the treatment of atherosclerosis, orthopedic postoperative infections, and

Indexed as

Anti-Inflammatory AgentsBacteriaBiological ProductsCytokinesHumansInflammationAnti-Inflammatory AgentsBiological ProductsCytokinesanti-inflammatory activitybacterial natural materialscytokinedrug-like activitysecondary metabolite

Identifiers

PMID32982183
PMCPMC7509312
OpenAlexW3086647146

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.